ATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovat

Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market ses

https://www.sec.gov/Archives/edgar/data/1339005/000114036126035625/ny20081537x1_s3.htm

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fert

FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent b

Gainers ZeroStack (NASDAQ:ZSTK) stock increased by 440.2% to $9.94 during Wednesday's regular s

Femasys (NASDAQ:FEMY) reported quarterly losses of $(1.08) per share which beat the analyst consensu

Maxim Group analyst Jason McCarthy maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the pric

 Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and

Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re

Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgi

The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shi

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.06) per share which beat the analyst consensu

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg

Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating

-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven t

-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility trea

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical perman

Femasys Inc. (NASDAQ: FEMY) ("Femasys" or the "Company"), a leading biomedical innov

Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane

-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support f

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announ

Laidlaw & Co. analyst Yale Jen initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.10) per share which beat the analyst consensu

Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane

https://www.nytimes.com/2025/10/16/us/politics/trump-ivf-fertility.html

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical perman

Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane